IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v41y2023i10d10.1007_s40273-023-01302-6.html
   My bibliography  Save this article

An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year

Author

Listed:
  • Jonathan D. Campbell

    (Institute for Clinical and Economic Review)

  • Melanie D. Whittington

    (Institute for Clinical and Economic Review)

  • Steven D. Pearson

    (Institute for Clinical and Economic Review)

Abstract

The quality-adjusted life-year (QALY) is an international standard in cost-effectiveness analysis. A known concern arises from the relatively lower QALY gains attributed to treatments that extend the life of individuals with chronic disability. We analyze here the advantages and disadvantages of the equal value life-year (evLY) as an alternative or a complementary measure to the QALY, and share learned experiences from using this measure in health technology assessments. We present the conceptual rationale for the evLY, describe how it is estimated, and assess the differences in results between analyses based on the evLY and the QALY. We share a how-to guide in estimating the evLY using a downloadable tool and summarize our empirical experience using this measure. Incremental evLYs are feasible and address concerns regarding the risk for a cost-effectiveness analysis to undervalue treatments for people with chronic disabilities. Based on our set of analyses using the evLY, a threshold of $84,000 per evLY gained would be needed to maintain alignment with a threshold of $100,000 per added QALY. The evLY is a measure of health gain that can be used as an alternative or a complement to the QALY to address concerns related to undervaluing treatments that extend the life of individuals with serious illness or chronic disability. We recommend that it be reported within all cost-effectiveness analyses but may have special relevance in the current political environment in the USA, where use of the QALY is often challenged or prohibited.

Suggested Citation

  • Jonathan D. Campbell & Melanie D. Whittington & Steven D. Pearson, 2023. "An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year," PharmacoEconomics, Springer, vol. 41(10), pages 1175-1182, October.
    • Handle: RePEc:spr:pharme:v:41:y:2023:i:10:d:10.1007_s40273-023-01302-6
    DOI: 10.1007/s40273-023-01302-6
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-023-01302-6
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-023-01302-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Erik Nord & Jose Luis Pinto & Jeff Richardson & Paul Menzel & Peter Ubel, 1999. "Incorporating societal concerns for fairness in numerical valuations of health programmes," Health Economics, John Wiley & Sons, Ltd., vol. 8(1), pages 25-39, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Erik Nord, 2015. "Cost-Value Analysis of Health Interventions: Introduction and Update on Methods and Preference Data," PharmacoEconomics, Springer, vol. 33(2), pages 89-95, February.
    2. Michaël Schwarzinger & Jean‐Louis Lanoë & Erik Nord & Isabelle Durand‐Zaleski, 2004. "Lack of multiplicative transitivity in person trade‐off responses," Health Economics, John Wiley & Sons, Ltd., vol. 13(2), pages 171-181, February.
    3. Damschroder, Laura J. & Zikmund-Fisher, Brian J. & Ubel, Peter A., 2005. "The impact of considering adaptation in health state valuation," Social Science & Medicine, Elsevier, vol. 61(2), pages 267-277, July.
    4. Klingler, Corinna & Shah, Sara M.B. & Barron, Anthony J.G. & Wright, John S.F., 2013. "Regulatory space and the contextual mediation of common functional pressures: Analyzing the factors that led to the German Efficiency Frontier approach," Health Policy, Elsevier, vol. 109(3), pages 270-280.
    5. Mæstad, Ottar & Norheim, Ole Frithjof, 2009. "Eliciting people's preferences for the distribution of health: A procedure for a more precise estimation of distributional weights," Journal of Health Economics, Elsevier, vol. 28(3), pages 570-577, May.
    6. Magnus Johannesson, 2001. "Should we aggregate relative or absolute changes in QALYs?," Health Economics, John Wiley & Sons, Ltd., vol. 10(7), pages 573-577, October.
    7. Francis Asenso‐Boadi & Tim J. Peters & Joanna Coast, 2008. "Exploring differences in empirical time preference rates for health: an application of meta‐regression," Health Economics, John Wiley & Sons, Ltd., vol. 17(2), pages 235-248, February.
    8. McTaggart-Cowan, Helen & Tsuchiya, Aki & O'Cathain, Alicia & Brazier, John, 2011. "Understanding the effect of disease adaptation information on general population values for hypothetical health states," Social Science & Medicine, Elsevier, vol. 72(11), pages 1904-1912, June.
    9. Duncan Mortimer, 2006. "The Value of Thinly Spread QALYs," PharmacoEconomics, Springer, vol. 24(9), pages 845-853, September.
    10. Hansen, Lise Desireé & Kjær, Trine, 2019. "Disentangling public preferences for health gains at end-of-life: Further evidence of no support of an end-of-life premium," Social Science & Medicine, Elsevier, vol. 236(C), pages 1-1.
    11. Mansdotter, Anna & Lindholm, Lars & Ohman, Ann, 2004. "Women, men and public health--how the choice of normative theory affects resource allocation," Health Policy, Elsevier, vol. 69(3), pages 351-364, September.
    12. Colin Green, 2001. "On the societal value of health care: what do we know about the person trade‐off technique?," Health Economics, John Wiley & Sons, Ltd., vol. 10(3), pages 233-243, April.
    13. Paul Dolan & Rebecca Shaw & Aki Tsuchiya & Alan Williams, 2005. "QALY maximisation and people's preferences: a methodological review of the literature," Health Economics, John Wiley & Sons, Ltd., vol. 14(2), pages 197-208, February.
    14. Andrew M. Jones (ed.), 2012. "The Elgar Companion to Health Economics, Second Edition," Books, Edward Elgar Publishing, number 14021, December.
    15. Abellán Perpiñán, José Mª & Sánchez Martínez,Fernando I. & Martínez Pérez, Jorge E., 2007. "La medición del bienestar social relacionado con la salud/The Measurement of the Health Related Social Welfare," Estudios de Economia Aplicada, Estudios de Economia Aplicada, vol. 25, pages 927-950, Diciembre.
    16. Pinto-Prades, Jose Luis & Loomes, Graham & Brey, Raul, 2009. "Trying to estimate a monetary value for the QALY," Journal of Health Economics, Elsevier, vol. 28(3), pages 553-562, May.
    17. Laura J. Damschroder & Jonathan Baron & John C. Hershey & David A. Asch & Christopher Jepson & Peter A. Ubel, 2004. "The Validity of Person Tradeoff Measurements: Randomized Trial of Computer Elicitation Versus Face-to-Face Interview," Medical Decision Making, , vol. 24(2), pages 170-180, March.
    18. Erik Nord & Paul Menzel & Jeff Richardson, 2006. "Multi‐method approach to valuing health states: problems with meaning," Health Economics, John Wiley & Sons, Ltd., vol. 15(2), pages 215-218, February.
    19. Edlin, Richard, 2004. "Anti-social welfare functions: a reply to Hansen et al," Journal of Health Economics, Elsevier, vol. 23(5), pages 899-905, September.
    20. Attema, Arthur E. & Brouwer, Werner B.F. & l’Haridon, Olivier & Pinto, Jose Luis, 2015. "Estimating sign-dependent societal preferences for quality of life," Journal of Health Economics, Elsevier, vol. 43(C), pages 229-243.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:41:y:2023:i:10:d:10.1007_s40273-023-01302-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.